The administration of rMIF into Mif−/− mice fully restored the resistance to acute toxoplasmosis, which highlights the crucial role of this inflammatory mediator in the development of the protective cell-mediated immune response to T. gondii and indicates a potential use of rMIF as a therapeutic tool on immune-compromised hosts to control toxoplasmosis and probably other protozoan infectious diseases. Here, MIF is linked to toxoplasmosis.